Investegate |Infant Bacterial Therapeutics Announcements | Infant Bacterial Therapeutics: Infant Bacterial Therapeutics receives additional patent protection in China investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Infant Bacterial Therapeutics AB: Infant Bacterial Therapeutics publishes Annual Report for 2020
The report is available on IBT s website
ibtherapeutics.comunder the section Investors & Media - Financial Reports and is available in printed form for those that have requested. A copy can be requested by contacting IBT s office via info@ibtherapeutics.com.
About Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) is a pharmaceutical company with a product in clinical stage with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants.
IBT is currently developing the drug candidate IBP-9414, for the prevention of necrotizing enterocolitis ( NEC ) and improvement of feeding tolerance in premature infants. IBP-9414 contains the active substance
Notice to attend the Annual General Meeting of Infant Bacterial Therapeutics
Shareholders of Infant Bacterial Therapeutics AB (publ) are summoned to the Annual General Meeting on Tuesday, May 4, 2021. In light of the coronavirus, the Annual General Meeting is conducted through advance voting pursuant to temporary regulations. Therefore, it will not be possible to attend this year’s Meeting in person or by proxy.
Right to participate
In order to participate in the Annual General Meeting (AGM) shareholders must be recorded in the shareholder register maintained by Euroclear Sweden AB no later than Monday April 26, 2021 and register for the meeting no later than on Monday May 3 by submitting an advance voting form in accordance with the instructions set forth in the section “Advance voting” below.
Infant Bacterial Therapeutics AB: Notice to attend the Annual General Meeting of Infant Bacterial Therapeutics
Shareholders of Infant Bacterial Therapeutics AB (publ) are summoned to the Annual General Meeting on Tuesday, May 4, 2021. In light of the coronavirus, the Annual General Meeting is conducted through advance voting pursuant to temporary regulations. Therefore, it will not be possible to attend this year s Meeting in person or by proxy.
Right to participate In order to participate in the Annual General Meeting (AGM) shareholders must be recorded in the shareholder register maintained by Euroclear Sweden AB no later than Monday April 26, 2021 and register for the meeting no later than on Monday May 3 by submitting an advance voting form in accordance with the instructions set forth in the section Advance voting below.
Infant Bacterial Therapeutics today announces that new patent protection is granted in Japan
Infant Bacterial Therapeutics AB today announces that the Japan Patent Office has issued a decision to grant a patent entitled: A method of activating lactic acid bacteria, which protects the formulation of
Lactobacillus reuteri including IBP-9414. IBT is currently developing its drug candidate IBP-9414 in Phase III for the prevention of NEC and improvement of feeding tolerance in preterm infants.
The invention covers a novel way to activate the freeze-dried bacteria and corresponding patent applications for the invention are currently pending in additional important future markets including the US and Europe. This patent further increases the existing protection of IBTs drug candidate IBP-9414 for which both Orphan Drug Exclusivity and biological data protection have been granted in the USA and EU.